Metformin regulates inflammation and fibrosis in diabetic kidney disease through TNC/TLR4/NF-κB/miR-155-5p inflammatory loop

doi:10.4239/wjd.v12.i1.19

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9230)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-12) series, Tables (1-6) series.

Item

Count

PDF

524

WORD

298

HTML

5147

Figures (1-12)

412

Tables (1-6)

353

Sum=6734

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

385

Download

780

Sum=1165

Publishing Process of This Article

Item

Count

Browse

514

Download

817

Sum=1331

Jan 15, 2021 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (42)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Diabetes. Jan 15, 2021; 12(1): 19-46
Published online Jan 15, 2021. doi: 10.4239/wjd.v12.i1.19

Table 2 Comparison of clinical characteristics and biochemical data among groups [mean ± SEM, M (quartile)]

Group	n	Age (yr)	TG (mmol/L)	TC (mmol/L)	LDL-C (mmol/L)	HDL-C (mmol/L)	UA (μmol/L)	HbA1C (%)	TNC (pg/mL)	UACR (mg/g)	SBP (mmHg)	DBP (mmHg)	HOMA-IR
A	60	50 ± 1.29	1.17 (0.92-1.48)	4.58 ± 0.11	2.80 ± 0.11	1.44 ± 0.05	279.54 ± 8.43	5.40 (5.25-5.70)	15.20 (14.08-15.95)	9.92 (7.58-11.23)	119 ± 1.55	72 ± 1.29	1.02 ± 0.08
B	70	52 ± 1.79	0.91 (0.71-1.59)	5.13 ± 0.15	3.40 ± 0.14	1.29 ± 0.04	265.77 ± 7.08	7.30 (6.05-8.70)^a	15.07 (12.10-17.95)	16.76 (13.58-24.26)^a	118 ± 1.79	74 ± 0.84	2.53 ± 0.12^a
C	105	56 ± 1.07	2.07 (1.32-3.01)^a^,^b	4.62 ± 0.07	2.88 ± 0.06	1.12 ± 0.03^a	340.24 ± 8.17^a^,^b	8.40 (7.50-9.80)^a	17.07 (14.70-19.88)^a^,^b	44.85 (33.91-59.59)^a^,^b	126 ± 0.68	77 ± 0.68	4.68 ± 0.26^a^,^b
D	75	57 ± 1.5	1.84 (1.55-3.87)^a^,^b	4.49 ± 0.13	2.89 ± 0.11	1.00 ± 0.02^a^,^b	348.87 ± 10.83^a^,^b	7.30 (6.60-8.50)^a	18.96 (14.70-21.40)^a^,^b^,^c	56.17 (45.80-159.74)^a^,^b^,^c	152 ± 1.04^a^,^b^,^c	92 ± 1.5^a^,^b^,^c	4.85 ± 0.34^a^,^b
E	65	52 ± 0.99	2.08 (1.76-2.88)^a^,^b	5.61 ± 0.16^a^,^c^,^d	3.68 ± 0.13^a^,^c^,^d	1.21 ± 0.03	381.11 ± 10.47^a^,^b	7.80 (7.00-9.25)^a	18.71 (16.40-19.95)^a^,^b^,^c	871.58 (390.94-871.58)^a^,^b^,^c^,^d	127 ± 1.36	79 ± 0.99	5.65 ± 0.45^a^,^b
F	65	59 ± 1.36	1.99 (1.38-4.07)^a^,^b	4.84 ± 0.15	2.84 ± 0.12^e	1.11 ± 0.04^a	358.38 ± 8.27^a^,^b	9.10 (7.10-9.70)^a	21.16 (16.92-21.35)^a^,^b^,^c^,^d^,^e	1094.62 (790.00-5246.40)^a^,^b^,^c^,^d^,^e	160 ± 1.49^a^,^b^,^c^,^e	96 ± 1.86^a^,^b^,^c^,^e	5.75 ± 0.4^a^,^b

^aP < 0.05 compared with group A.

^bP < 0.05 compared with group B.

^cP < 0.05 compared with group C.

^dP < 0.05 compared with group D.

^eP < 0.05 compared with group E. 1 mmHg = 0.133 kPa; A: Healthy group; B: Normal albuminuria group; C: Microalbuminuria group; D: Microalbuminuria combined with hypertension group; E: Macroalbuminuria group; F: Macroalbuminuria combined with hypertension group. BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; UACR: Urinary albumin to creatinine ratio; HOMA-IR: Homeostasis model assessment-insulin resistance; HOMA-IR: Homeostasis model assessment of insulin resistance, = FRG × FINS / 22.5; HDL-C: High-density lipoprotein-cholesterol; LDL-C: Low-density lipoprotein-cholesterol; TC: Total cholesterol; TG: Triglycerides; UA: Uric acid; TNC: Tenascin-C.

Citation: Zhou Y, Ma XY, Han JY, Yang M, Lv C, Shao Y, Wang YL, Kang JY, Wang QY. Metformin regulates inflammation and fibrosis in diabetic kidney disease through TNC/TLR4/NF-κB/miR-155-5p inflammatory loop. World J Diabetes 2021; 12(1): 19-46
URL: https://www.wjgnet.com/1948-9358/full/v12/i1/19.htm
DOI: https://dx.doi.org/10.4239/wjd.v12.i1.19